nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA2—osteoporosis	0.276	1	CbGaD
Nilotinib—CA14—Zoledronate—osteoporosis	0.0883	0.224	CbGbCtD
Nilotinib—CA12—Zoledronate—osteoporosis	0.0627	0.159	CbGbCtD
Nilotinib—CA2—Zoledronate—osteoporosis	0.0507	0.129	CbGbCtD
Nilotinib—UGT1A1—Estradiol—osteoporosis	0.0214	0.0544	CbGbCtD
Nilotinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0134	0.0341	CbGbCtD
Nilotinib—CYP2B6—Raloxifene—osteoporosis	0.0133	0.0338	CbGbCtD
Nilotinib—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0129	0.0327	CbGbCtD
Nilotinib—ABCG2—Estradiol—osteoporosis	0.0118	0.0299	CbGbCtD
Nilotinib—CYP2C9—Estropipate—osteoporosis	0.0105	0.0268	CbGbCtD
Nilotinib—CYP2B6—Cholecalciferol—osteoporosis	0.0103	0.0261	CbGbCtD
Nilotinib—CYP2C8—Raloxifene—osteoporosis	0.0101	0.0256	CbGbCtD
Nilotinib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.00973	0.0247	CbGbCtD
Nilotinib—CYP2C8—Cholecalciferol—osteoporosis	0.00778	0.0198	CbGbCtD
Nilotinib—MAPK8—periosteum—osteoporosis	0.00684	0.226	CbGeAlD
Nilotinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.00659	0.0167	CbGbCtD
Nilotinib—CYP2C8—Estradiol—osteoporosis	0.00627	0.0159	CbGbCtD
Nilotinib—CYP3A4—Estropipate—osteoporosis	0.00613	0.0156	CbGbCtD
Nilotinib—CYP3A4—Calcitriol—osteoporosis	0.00613	0.0156	CbGbCtD
Nilotinib—CYP2C9—Cholecalciferol—osteoporosis	0.00543	0.0138	CbGbCtD
Nilotinib—CYP2D6—Cholecalciferol—osteoporosis	0.00496	0.0126	CbGbCtD
Nilotinib—CYP3A4—Ergocalciferol—osteoporosis	0.0049	0.0124	CbGbCtD
Nilotinib—ABCB1—Conjugated Estrogens—osteoporosis	0.00484	0.0123	CbGbCtD
Nilotinib—CYP2C9—Estradiol—osteoporosis	0.00437	0.0111	CbGbCtD
Nilotinib—ABCB1—Estradiol—osteoporosis	0.00425	0.0108	CbGbCtD
Nilotinib—CYP3A4—Raloxifene—osteoporosis	0.00409	0.0104	CbGbCtD
Nilotinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00395	0.01	CbGbCtD
Nilotinib—CYP3A4—Cholecalciferol—osteoporosis	0.00316	0.00802	CbGbCtD
Nilotinib—CSF1R—periosteum—osteoporosis	0.00314	0.104	CbGeAlD
Nilotinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0029	0.00736	CbGbCtD
Nilotinib—CYP3A4—Estradiol—osteoporosis	0.00254	0.00647	CbGbCtD
Nilotinib—CA2—periosteum—osteoporosis	0.00169	0.0559	CbGeAlD
Nilotinib—Imatinib—CA2—osteoporosis	0.00113	1	CrCbGaD
Nilotinib—CDC42BPB—uterus—osteoporosis	0.00103	0.0342	CbGeAlD
Nilotinib—MAPK8—uterus—osteoporosis	0.000935	0.0309	CbGeAlD
Nilotinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000847	1	CbGdCrCtD
Nilotinib—TIE1—uterus—osteoporosis	0.000811	0.0268	CbGeAlD
Nilotinib—MAPK8—bone marrow—osteoporosis	0.000794	0.0262	CbGeAlD
Nilotinib—BRAF—uterus—osteoporosis	0.000777	0.0257	CbGeAlD
Nilotinib—EPHB3—uterus—osteoporosis	0.000771	0.0255	CbGeAlD
Nilotinib—MAP4K1—bone marrow—osteoporosis	0.000721	0.0238	CbGeAlD
Nilotinib—HCK—uterus—osteoporosis	0.000709	0.0234	CbGeAlD
Nilotinib—BRAF—bone marrow—osteoporosis	0.00066	0.0218	CbGeAlD
Nilotinib—EPHA4—uterus—osteoporosis	0.000644	0.0213	CbGeAlD
Nilotinib—CA3—uterus—osteoporosis	0.000636	0.021	CbGeAlD
Nilotinib—HCK—bone marrow—osteoporosis	0.000601	0.0199	CbGeAlD
Nilotinib—MAPK14—uterus—osteoporosis	0.000594	0.0196	CbGeAlD
Nilotinib—LCK—uterus—osteoporosis	0.000591	0.0196	CbGeAlD
Nilotinib—EPHB4—uterus—osteoporosis	0.000563	0.0186	CbGeAlD
Nilotinib—CA3—bone marrow—osteoporosis	0.00054	0.0179	CbGeAlD
Nilotinib—TEK—uterus—osteoporosis	0.000539	0.0178	CbGeAlD
Nilotinib—MAPK14—bone marrow—osteoporosis	0.000504	0.0167	CbGeAlD
Nilotinib—LCK—bone marrow—osteoporosis	0.000502	0.0166	CbGeAlD
Nilotinib—FGR—bone marrow—osteoporosis	0.000502	0.0166	CbGeAlD
Nilotinib—PDGFRA—uterus—osteoporosis	0.000488	0.0161	CbGeAlD
Nilotinib—EPHB4—bone marrow—osteoporosis	0.000478	0.0158	CbGeAlD
Nilotinib—CSF1R—uterus—osteoporosis	0.00043	0.0142	CbGeAlD
Nilotinib—KIT—uterus—osteoporosis	0.00039	0.0129	CbGeAlD
Nilotinib—PDGFRB—uterus—osteoporosis	0.000381	0.0126	CbGeAlD
Nilotinib—CSF1R—bone marrow—osteoporosis	0.000365	0.0121	CbGeAlD
Nilotinib—ABL1—uterus—osteoporosis	0.00034	0.0112	CbGeAlD
Nilotinib—KIT—bone marrow—osteoporosis	0.000331	0.011	CbGeAlD
Nilotinib—PDGFRB—bone marrow—osteoporosis	0.000323	0.0107	CbGeAlD
Nilotinib—CA1—bone marrow—osteoporosis	0.000303	0.01	CbGeAlD
Nilotinib—ABL1—bone marrow—osteoporosis	0.000288	0.00953	CbGeAlD
Nilotinib—CA4—bone marrow—osteoporosis	0.000237	0.00783	CbGeAlD
Nilotinib—ABCG2—uterus—osteoporosis	0.000214	0.00708	CbGeAlD
Nilotinib—CA2—bone marrow—osteoporosis	0.000196	0.00649	CbGeAlD
Nilotinib—ABCG2—bone marrow—osteoporosis	0.000182	0.00601	CbGeAlD
Nilotinib—ABCB1—uterus—osteoporosis	0.000106	0.00349	CbGeAlD
Nilotinib—ABCB1—bone marrow—osteoporosis	8.97e-05	0.00296	CbGeAlD
Nilotinib—Pruritus—Estropipate—osteoporosis	7.25e-05	0.000451	CcSEcCtD
Nilotinib—Discomfort—Zoledronate—osteoporosis	7.24e-05	0.000451	CcSEcCtD
Nilotinib—Asthenia—Alendronate—osteoporosis	7.24e-05	0.00045	CcSEcCtD
Nilotinib—Hypersensitivity—Ibandronate—osteoporosis	7.24e-05	0.00045	CcSEcCtD
Nilotinib—Cough—Conjugated Estrogens—osteoporosis	7.24e-05	0.00045	CcSEcCtD
Nilotinib—Dyspnoea—Risedronate—osteoporosis	7.22e-05	0.000449	CcSEcCtD
Nilotinib—Erythema multiforme—Estradiol—osteoporosis	7.21e-05	0.000449	CcSEcCtD
Nilotinib—Hypotension—Pamidronate—osteoporosis	7.19e-05	0.000447	CcSEcCtD
Nilotinib—Dry mouth—Zoledronate—osteoporosis	7.17e-05	0.000446	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	7.17e-05	0.000446	CcSEcCtD
Nilotinib—Fatigue—Ethinyl Estradiol—osteoporosis	7.16e-05	0.000445	CcSEcCtD
Nilotinib—Pruritus—Alendronate—osteoporosis	7.14e-05	0.000444	CcSEcCtD
Nilotinib—Dyspepsia—Risedronate—osteoporosis	7.12e-05	0.000443	CcSEcCtD
Nilotinib—Eye disorder—Estradiol—osteoporosis	7.12e-05	0.000443	CcSEcCtD
Nilotinib—Tinnitus—Estradiol—osteoporosis	7.11e-05	0.000442	CcSEcCtD
Nilotinib—Constipation—Ethinyl Estradiol—osteoporosis	7.1e-05	0.000442	CcSEcCtD
Nilotinib—Confusional state—Zoledronate—osteoporosis	7.09e-05	0.000441	CcSEcCtD
Nilotinib—Hypersensitivity—Calcitriol—osteoporosis	7.08e-05	0.000441	CcSEcCtD
Nilotinib—Flushing—Estradiol—osteoporosis	7.08e-05	0.00044	CcSEcCtD
Nilotinib—Cardiac disorder—Estradiol—osteoporosis	7.08e-05	0.00044	CcSEcCtD
Nilotinib—Arthralgia—Conjugated Estrogens—osteoporosis	7.06e-05	0.000439	CcSEcCtD
Nilotinib—Myalgia—Conjugated Estrogens—osteoporosis	7.06e-05	0.000439	CcSEcCtD
Nilotinib—Chest pain—Conjugated Estrogens—osteoporosis	7.06e-05	0.000439	CcSEcCtD
Nilotinib—Asthenia—Ibandronate—osteoporosis	7.05e-05	0.000439	CcSEcCtD
Nilotinib—Anxiety—Conjugated Estrogens—osteoporosis	7.04e-05	0.000438	CcSEcCtD
Nilotinib—Nausea—Etidronic acid—osteoporosis	7.03e-05	0.000438	CcSEcCtD
Nilotinib—Oedema—Zoledronate—osteoporosis	7.03e-05	0.000437	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	7.01e-05	0.000436	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	7.01e-05	0.000436	CcSEcCtD
Nilotinib—Diarrhoea—Estropipate—osteoporosis	7.01e-05	0.000436	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Risedronate—osteoporosis	6.99e-05	0.000435	CcSEcCtD
Nilotinib—Infection—Zoledronate—osteoporosis	6.98e-05	0.000435	CcSEcCtD
Nilotinib—Fatigue—Risedronate—osteoporosis	6.98e-05	0.000434	CcSEcCtD
Nilotinib—Insomnia—Pamidronate—osteoporosis	6.96e-05	0.000433	CcSEcCtD
Nilotinib—Pruritus—Ibandronate—osteoporosis	6.95e-05	0.000432	CcSEcCtD
Nilotinib—Pain—Risedronate—osteoporosis	6.92e-05	0.000431	CcSEcCtD
Nilotinib—Constipation—Risedronate—osteoporosis	6.92e-05	0.000431	CcSEcCtD
Nilotinib—Angiopathy—Estradiol—osteoporosis	6.92e-05	0.00043	CcSEcCtD
Nilotinib—Shock—Zoledronate—osteoporosis	6.91e-05	0.00043	CcSEcCtD
Nilotinib—Paraesthesia—Pamidronate—osteoporosis	6.91e-05	0.00043	CcSEcCtD
Nilotinib—Diarrhoea—Alendronate—osteoporosis	6.9e-05	0.00043	CcSEcCtD
Nilotinib—Asthenia—Calcitriol—osteoporosis	6.9e-05	0.000429	CcSEcCtD
Nilotinib—Nervous system disorder—Zoledronate—osteoporosis	6.89e-05	0.000429	CcSEcCtD
Nilotinib—Immune system disorder—Estradiol—osteoporosis	6.89e-05	0.000429	CcSEcCtD
Nilotinib—Thrombocytopenia—Zoledronate—osteoporosis	6.88e-05	0.000428	CcSEcCtD
Nilotinib—Mediastinal disorder—Estradiol—osteoporosis	6.87e-05	0.000428	CcSEcCtD
Nilotinib—Dyspnoea—Pamidronate—osteoporosis	6.86e-05	0.000427	CcSEcCtD
Nilotinib—Tachycardia—Zoledronate—osteoporosis	6.86e-05	0.000427	CcSEcCtD
Nilotinib—Feeling abnormal—Ethinyl Estradiol—osteoporosis	6.84e-05	0.000426	CcSEcCtD
Nilotinib—Chills—Estradiol—osteoporosis	6.84e-05	0.000426	CcSEcCtD
Nilotinib—Skin disorder—Zoledronate—osteoporosis	6.83e-05	0.000425	CcSEcCtD
Nilotinib—Pruritus—Calcitriol—osteoporosis	6.8e-05	0.000423	CcSEcCtD
Nilotinib—Hyperhidrosis—Zoledronate—osteoporosis	6.79e-05	0.000423	CcSEcCtD
Nilotinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	6.79e-05	0.000422	CcSEcCtD
Nilotinib—Diarrhoea—Raloxifene—osteoporosis	6.79e-05	0.000422	CcSEcCtD
Nilotinib—Dyspepsia—Pamidronate—osteoporosis	6.77e-05	0.000422	CcSEcCtD
Nilotinib—Dizziness—Estropipate—osteoporosis	6.77e-05	0.000421	CcSEcCtD
Nilotinib—Oedema—Conjugated Estrogens—osteoporosis	6.77e-05	0.000421	CcSEcCtD
Nilotinib—Alopecia—Estradiol—osteoporosis	6.74e-05	0.000419	CcSEcCtD
Nilotinib—Infection—Conjugated Estrogens—osteoporosis	6.72e-05	0.000418	CcSEcCtD
Nilotinib—Diarrhoea—Ibandronate—osteoporosis	6.72e-05	0.000418	CcSEcCtD
Nilotinib—Anorexia—Zoledronate—osteoporosis	6.7e-05	0.000417	CcSEcCtD
Nilotinib—Decreased appetite—Pamidronate—osteoporosis	6.69e-05	0.000416	CcSEcCtD
Nilotinib—Mental disorder—Estradiol—osteoporosis	6.68e-05	0.000416	CcSEcCtD
Nilotinib—Dizziness—Alendronate—osteoporosis	6.67e-05	0.000415	CcSEcCtD
Nilotinib—Shock—Conjugated Estrogens—osteoporosis	6.66e-05	0.000414	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Pamidronate—osteoporosis	6.64e-05	0.000413	CcSEcCtD
Nilotinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	6.64e-05	0.000413	CcSEcCtD
Nilotinib—Erythema—Estradiol—osteoporosis	6.64e-05	0.000413	CcSEcCtD
Nilotinib—Malnutrition—Estradiol—osteoporosis	6.64e-05	0.000413	CcSEcCtD
Nilotinib—Fatigue—Pamidronate—osteoporosis	6.63e-05	0.000413	CcSEcCtD
Nilotinib—Gastrointestinal pain—Risedronate—osteoporosis	6.62e-05	0.000412	CcSEcCtD
Nilotinib—Tachycardia—Conjugated Estrogens—osteoporosis	6.6e-05	0.000411	CcSEcCtD
Nilotinib—Urticaria—Ethinyl Estradiol—osteoporosis	6.59e-05	0.00041	CcSEcCtD
Nilotinib—Pain—Pamidronate—osteoporosis	6.58e-05	0.000409	CcSEcCtD
Nilotinib—Constipation—Pamidronate—osteoporosis	6.58e-05	0.000409	CcSEcCtD
Nilotinib—Diarrhoea—Calcitriol—osteoporosis	6.58e-05	0.000409	CcSEcCtD
Nilotinib—Skin disorder—Conjugated Estrogens—osteoporosis	6.57e-05	0.000409	CcSEcCtD
Nilotinib—Hypotension—Zoledronate—osteoporosis	6.57e-05	0.000409	CcSEcCtD
Nilotinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	6.56e-05	0.000408	CcSEcCtD
Nilotinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	6.56e-05	0.000408	CcSEcCtD
Nilotinib—Dizziness—Raloxifene—osteoporosis	6.56e-05	0.000408	CcSEcCtD
Nilotinib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	6.54e-05	0.000407	CcSEcCtD
Nilotinib—Flatulence—Estradiol—osteoporosis	6.54e-05	0.000407	CcSEcCtD
Nilotinib—Vomiting—Estropipate—osteoporosis	6.51e-05	0.000405	CcSEcCtD
Nilotinib—Dysgeusia—Estradiol—osteoporosis	6.5e-05	0.000404	CcSEcCtD
Nilotinib—Dizziness—Ibandronate—osteoporosis	6.49e-05	0.000404	CcSEcCtD
Nilotinib—Rash—Estropipate—osteoporosis	6.46e-05	0.000402	CcSEcCtD
Nilotinib—Dermatitis—Estropipate—osteoporosis	6.45e-05	0.000402	CcSEcCtD
Nilotinib—Anorexia—Conjugated Estrogens—osteoporosis	6.45e-05	0.000401	CcSEcCtD
Nilotinib—Urticaria—Risedronate—osteoporosis	6.43e-05	0.0004	CcSEcCtD
Nilotinib—Back pain—Estradiol—osteoporosis	6.42e-05	0.000399	CcSEcCtD
Nilotinib—Headache—Estropipate—osteoporosis	6.42e-05	0.000399	CcSEcCtD
Nilotinib—Vomiting—Alendronate—osteoporosis	6.41e-05	0.000399	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	6.4e-05	0.000398	CcSEcCtD
Nilotinib—Abdominal pain—Risedronate—osteoporosis	6.4e-05	0.000398	CcSEcCtD
Nilotinib—Body temperature increased—Risedronate—osteoporosis	6.4e-05	0.000398	CcSEcCtD
Nilotinib—Muscle spasms—Estradiol—osteoporosis	6.38e-05	0.000397	CcSEcCtD
Nilotinib—Rash—Alendronate—osteoporosis	6.36e-05	0.000396	CcSEcCtD
Nilotinib—Insomnia—Zoledronate—osteoporosis	6.36e-05	0.000396	CcSEcCtD
Nilotinib—Dermatitis—Alendronate—osteoporosis	6.35e-05	0.000395	CcSEcCtD
Nilotinib—Feeling abnormal—Pamidronate—osteoporosis	6.34e-05	0.000395	CcSEcCtD
Nilotinib—Hypotension—Conjugated Estrogens—osteoporosis	6.32e-05	0.000394	CcSEcCtD
Nilotinib—Headache—Alendronate—osteoporosis	6.32e-05	0.000393	CcSEcCtD
Nilotinib—Paraesthesia—Zoledronate—osteoporosis	6.31e-05	0.000393	CcSEcCtD
Nilotinib—Vomiting—Raloxifene—osteoporosis	6.31e-05	0.000393	CcSEcCtD
Nilotinib—Gastrointestinal pain—Pamidronate—osteoporosis	6.29e-05	0.000392	CcSEcCtD
Nilotinib—Dyspnoea—Zoledronate—osteoporosis	6.27e-05	0.00039	CcSEcCtD
Nilotinib—Rash—Raloxifene—osteoporosis	6.26e-05	0.000389	CcSEcCtD
Nilotinib—Dermatitis—Raloxifene—osteoporosis	6.25e-05	0.000389	CcSEcCtD
Nilotinib—Vomiting—Ibandronate—osteoporosis	6.24e-05	0.000389	CcSEcCtD
Nilotinib—Tremor—Estradiol—osteoporosis	6.22e-05	0.000387	CcSEcCtD
Nilotinib—Headache—Raloxifene—osteoporosis	6.22e-05	0.000387	CcSEcCtD
Nilotinib—Rash—Ibandronate—osteoporosis	6.19e-05	0.000385	CcSEcCtD
Nilotinib—Dermatitis—Ibandronate—osteoporosis	6.19e-05	0.000385	CcSEcCtD
Nilotinib—Dyspepsia—Zoledronate—osteoporosis	6.19e-05	0.000385	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	6.17e-05	0.000384	CcSEcCtD
Nilotinib—Ill-defined disorder—Estradiol—osteoporosis	6.16e-05	0.000383	CcSEcCtD
Nilotinib—Headache—Ibandronate—osteoporosis	6.15e-05	0.000383	CcSEcCtD
Nilotinib—Insomnia—Conjugated Estrogens—osteoporosis	6.12e-05	0.000381	CcSEcCtD
Nilotinib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	6.12e-05	0.000381	CcSEcCtD
Nilotinib—Vomiting—Calcitriol—osteoporosis	6.11e-05	0.00038	CcSEcCtD
Nilotinib—Decreased appetite—Zoledronate—osteoporosis	6.11e-05	0.00038	CcSEcCtD
Nilotinib—Nausea—Estropipate—osteoporosis	6.08e-05	0.000379	CcSEcCtD
Nilotinib—Body temperature increased—Pamidronate—osteoporosis	6.08e-05	0.000379	CcSEcCtD
Nilotinib—Abdominal pain—Pamidronate—osteoporosis	6.08e-05	0.000379	CcSEcCtD
Nilotinib—Paraesthesia—Conjugated Estrogens—osteoporosis	6.08e-05	0.000378	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Zoledronate—osteoporosis	6.07e-05	0.000378	CcSEcCtD
Nilotinib—Rash—Calcitriol—osteoporosis	6.06e-05	0.000377	CcSEcCtD
Nilotinib—Fatigue—Zoledronate—osteoporosis	6.06e-05	0.000377	CcSEcCtD
Nilotinib—Dermatitis—Calcitriol—osteoporosis	6.06e-05	0.000377	CcSEcCtD
Nilotinib—Dyspnoea—Conjugated Estrogens—osteoporosis	6.03e-05	0.000375	CcSEcCtD
Nilotinib—Headache—Calcitriol—osteoporosis	6.02e-05	0.000375	CcSEcCtD
Nilotinib—Pain—Zoledronate—osteoporosis	6.01e-05	0.000374	CcSEcCtD
Nilotinib—Constipation—Zoledronate—osteoporosis	6.01e-05	0.000374	CcSEcCtD
Nilotinib—Nausea—Alendronate—osteoporosis	5.99e-05	0.000373	CcSEcCtD
Nilotinib—Malaise—Estradiol—osteoporosis	5.98e-05	0.000372	CcSEcCtD
Nilotinib—Hypersensitivity—Risedronate—osteoporosis	5.96e-05	0.000371	CcSEcCtD
Nilotinib—Vertigo—Estradiol—osteoporosis	5.96e-05	0.000371	CcSEcCtD
Nilotinib—Dyspepsia—Conjugated Estrogens—osteoporosis	5.96e-05	0.000371	CcSEcCtD
Nilotinib—Asthenia—Ethinyl Estradiol—osteoporosis	5.96e-05	0.000371	CcSEcCtD
Nilotinib—Syncope—Estradiol—osteoporosis	5.95e-05	0.00037	CcSEcCtD
Nilotinib—Nausea—Raloxifene—osteoporosis	5.89e-05	0.000367	CcSEcCtD
Nilotinib—Decreased appetite—Conjugated Estrogens—osteoporosis	5.88e-05	0.000366	CcSEcCtD
Nilotinib—Pruritus—Ethinyl Estradiol—osteoporosis	5.87e-05	0.000366	CcSEcCtD
Nilotinib—Palpitations—Estradiol—osteoporosis	5.86e-05	0.000365	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	5.84e-05	0.000364	CcSEcCtD
Nilotinib—Fatigue—Conjugated Estrogens—osteoporosis	5.83e-05	0.000363	CcSEcCtD
Nilotinib—Nausea—Ibandronate—osteoporosis	5.83e-05	0.000363	CcSEcCtD
Nilotinib—Loss of consciousness—Estradiol—osteoporosis	5.83e-05	0.000363	CcSEcCtD
Nilotinib—Asthenia—Risedronate—osteoporosis	5.81e-05	0.000361	CcSEcCtD
Nilotinib—Feeling abnormal—Zoledronate—osteoporosis	5.79e-05	0.00036	CcSEcCtD
Nilotinib—Cough—Estradiol—osteoporosis	5.79e-05	0.00036	CcSEcCtD
Nilotinib—Pain—Conjugated Estrogens—osteoporosis	5.79e-05	0.00036	CcSEcCtD
Nilotinib—Constipation—Conjugated Estrogens—osteoporosis	5.79e-05	0.00036	CcSEcCtD
Nilotinib—Gastrointestinal pain—Zoledronate—osteoporosis	5.75e-05	0.000358	CcSEcCtD
Nilotinib—Hypertension—Estradiol—osteoporosis	5.73e-05	0.000357	CcSEcCtD
Nilotinib—Pruritus—Risedronate—osteoporosis	5.73e-05	0.000356	CcSEcCtD
Nilotinib—Nausea—Calcitriol—osteoporosis	5.71e-05	0.000355	CcSEcCtD
Nilotinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	5.68e-05	0.000353	CcSEcCtD
Nilotinib—Hypersensitivity—Pamidronate—osteoporosis	5.67e-05	0.000353	CcSEcCtD
Nilotinib—Chest pain—Estradiol—osteoporosis	5.65e-05	0.000352	CcSEcCtD
Nilotinib—Arthralgia—Estradiol—osteoporosis	5.65e-05	0.000352	CcSEcCtD
Nilotinib—Myalgia—Estradiol—osteoporosis	5.65e-05	0.000352	CcSEcCtD
Nilotinib—Anxiety—Estradiol—osteoporosis	5.63e-05	0.00035	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	5.61e-05	0.000349	CcSEcCtD
Nilotinib—Urticaria—Zoledronate—osteoporosis	5.58e-05	0.000347	CcSEcCtD
Nilotinib—Discomfort—Estradiol—osteoporosis	5.58e-05	0.000347	CcSEcCtD
Nilotinib—Abdominal pain—Zoledronate—osteoporosis	5.56e-05	0.000346	CcSEcCtD
Nilotinib—Body temperature increased—Zoledronate—osteoporosis	5.56e-05	0.000346	CcSEcCtD
Nilotinib—Diarrhoea—Risedronate—osteoporosis	5.54e-05	0.000345	CcSEcCtD
Nilotinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	5.53e-05	0.000344	CcSEcCtD
Nilotinib—Dry mouth—Estradiol—osteoporosis	5.53e-05	0.000344	CcSEcCtD
Nilotinib—Asthenia—Pamidronate—osteoporosis	5.52e-05	0.000344	CcSEcCtD
Nilotinib—Dizziness—Ethinyl Estradiol—osteoporosis	5.49e-05	0.000342	CcSEcCtD
Nilotinib—Confusional state—Estradiol—osteoporosis	5.46e-05	0.00034	CcSEcCtD
Nilotinib—Pruritus—Pamidronate—osteoporosis	5.44e-05	0.000339	CcSEcCtD
Nilotinib—Oedema—Estradiol—osteoporosis	5.42e-05	0.000337	CcSEcCtD
Nilotinib—Infection—Estradiol—osteoporosis	5.38e-05	0.000335	CcSEcCtD
Nilotinib—Urticaria—Conjugated Estrogens—osteoporosis	5.38e-05	0.000335	CcSEcCtD
Nilotinib—Dizziness—Risedronate—osteoporosis	5.35e-05	0.000333	CcSEcCtD
Nilotinib—Abdominal pain—Conjugated Estrogens—osteoporosis	5.35e-05	0.000333	CcSEcCtD
Nilotinib—Body temperature increased—Conjugated Estrogens—osteoporosis	5.35e-05	0.000333	CcSEcCtD
Nilotinib—Shock—Estradiol—osteoporosis	5.33e-05	0.000332	CcSEcCtD
Nilotinib—Nervous system disorder—Estradiol—osteoporosis	5.31e-05	0.000331	CcSEcCtD
Nilotinib—Tachycardia—Estradiol—osteoporosis	5.29e-05	0.000329	CcSEcCtD
Nilotinib—Vomiting—Ethinyl Estradiol—osteoporosis	5.28e-05	0.000328	CcSEcCtD
Nilotinib—Diarrhoea—Pamidronate—osteoporosis	5.26e-05	0.000328	CcSEcCtD
Nilotinib—Skin disorder—Estradiol—osteoporosis	5.26e-05	0.000327	CcSEcCtD
Nilotinib—Hyperhidrosis—Estradiol—osteoporosis	5.24e-05	0.000326	CcSEcCtD
Nilotinib—Rash—Ethinyl Estradiol—osteoporosis	5.23e-05	0.000326	CcSEcCtD
Nilotinib—Dermatitis—Ethinyl Estradiol—osteoporosis	5.23e-05	0.000325	CcSEcCtD
Nilotinib—Headache—Ethinyl Estradiol—osteoporosis	5.2e-05	0.000324	CcSEcCtD
Nilotinib—Hypersensitivity—Zoledronate—osteoporosis	5.18e-05	0.000322	CcSEcCtD
Nilotinib—Vomiting—Risedronate—osteoporosis	5.15e-05	0.00032	CcSEcCtD
Nilotinib—Rash—Risedronate—osteoporosis	5.1e-05	0.000318	CcSEcCtD
Nilotinib—Dermatitis—Risedronate—osteoporosis	5.1e-05	0.000317	CcSEcCtD
Nilotinib—Dizziness—Pamidronate—osteoporosis	5.09e-05	0.000317	CcSEcCtD
Nilotinib—Headache—Risedronate—osteoporosis	5.07e-05	0.000316	CcSEcCtD
Nilotinib—Asthenia—Zoledronate—osteoporosis	5.04e-05	0.000314	CcSEcCtD
Nilotinib—Hypersensitivity—Conjugated Estrogens—osteoporosis	4.99e-05	0.00031	CcSEcCtD
Nilotinib—Pruritus—Zoledronate—osteoporosis	4.97e-05	0.000309	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Estradiol—osteoporosis	4.93e-05	0.000307	CcSEcCtD
Nilotinib—Nausea—Ethinyl Estradiol—osteoporosis	4.93e-05	0.000307	CcSEcCtD
Nilotinib—Insomnia—Estradiol—osteoporosis	4.9e-05	0.000305	CcSEcCtD
Nilotinib—Vomiting—Pamidronate—osteoporosis	4.89e-05	0.000304	CcSEcCtD
Nilotinib—Paraesthesia—Estradiol—osteoporosis	4.86e-05	0.000303	CcSEcCtD
Nilotinib—Asthenia—Conjugated Estrogens—osteoporosis	4.86e-05	0.000302	CcSEcCtD
Nilotinib—Rash—Pamidronate—osteoporosis	4.85e-05	0.000302	CcSEcCtD
Nilotinib—Dermatitis—Pamidronate—osteoporosis	4.85e-05	0.000302	CcSEcCtD
Nilotinib—Dyspnoea—Estradiol—osteoporosis	4.83e-05	0.000301	CcSEcCtD
Nilotinib—Headache—Pamidronate—osteoporosis	4.82e-05	0.0003	CcSEcCtD
Nilotinib—Diarrhoea—Zoledronate—osteoporosis	4.81e-05	0.000299	CcSEcCtD
Nilotinib—Nausea—Risedronate—osteoporosis	4.81e-05	0.000299	CcSEcCtD
Nilotinib—Pruritus—Conjugated Estrogens—osteoporosis	4.79e-05	0.000298	CcSEcCtD
Nilotinib—Dyspepsia—Estradiol—osteoporosis	4.77e-05	0.000297	CcSEcCtD
Nilotinib—Decreased appetite—Estradiol—osteoporosis	4.71e-05	0.000293	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Estradiol—osteoporosis	4.68e-05	0.000291	CcSEcCtD
Nilotinib—Fatigue—Estradiol—osteoporosis	4.67e-05	0.000291	CcSEcCtD
Nilotinib—Dizziness—Zoledronate—osteoporosis	4.65e-05	0.000289	CcSEcCtD
Nilotinib—Pain—Estradiol—osteoporosis	4.63e-05	0.000288	CcSEcCtD
Nilotinib—Constipation—Estradiol—osteoporosis	4.63e-05	0.000288	CcSEcCtD
Nilotinib—Diarrhoea—Conjugated Estrogens—osteoporosis	4.63e-05	0.000288	CcSEcCtD
Nilotinib—Nausea—Pamidronate—osteoporosis	4.57e-05	0.000284	CcSEcCtD
Nilotinib—Dizziness—Conjugated Estrogens—osteoporosis	4.48e-05	0.000279	CcSEcCtD
Nilotinib—Vomiting—Zoledronate—osteoporosis	4.47e-05	0.000278	CcSEcCtD
Nilotinib—Feeling abnormal—Estradiol—osteoporosis	4.46e-05	0.000278	CcSEcCtD
Nilotinib—Rash—Zoledronate—osteoporosis	4.43e-05	0.000276	CcSEcCtD
Nilotinib—Gastrointestinal pain—Estradiol—osteoporosis	4.43e-05	0.000276	CcSEcCtD
Nilotinib—Dermatitis—Zoledronate—osteoporosis	4.43e-05	0.000276	CcSEcCtD
Nilotinib—Headache—Zoledronate—osteoporosis	4.4e-05	0.000274	CcSEcCtD
Nilotinib—Vomiting—Conjugated Estrogens—osteoporosis	4.3e-05	0.000268	CcSEcCtD
Nilotinib—Urticaria—Estradiol—osteoporosis	4.3e-05	0.000268	CcSEcCtD
Nilotinib—Body temperature increased—Estradiol—osteoporosis	4.28e-05	0.000266	CcSEcCtD
Nilotinib—Abdominal pain—Estradiol—osteoporosis	4.28e-05	0.000266	CcSEcCtD
Nilotinib—Rash—Conjugated Estrogens—osteoporosis	4.27e-05	0.000266	CcSEcCtD
Nilotinib—Dermatitis—Conjugated Estrogens—osteoporosis	4.26e-05	0.000265	CcSEcCtD
Nilotinib—Headache—Conjugated Estrogens—osteoporosis	4.24e-05	0.000264	CcSEcCtD
Nilotinib—Nausea—Zoledronate—osteoporosis	4.17e-05	0.00026	CcSEcCtD
Nilotinib—Nausea—Conjugated Estrogens—osteoporosis	4.02e-05	0.00025	CcSEcCtD
Nilotinib—Hypersensitivity—Estradiol—osteoporosis	3.99e-05	0.000248	CcSEcCtD
Nilotinib—Asthenia—Estradiol—osteoporosis	3.89e-05	0.000242	CcSEcCtD
Nilotinib—Pruritus—Estradiol—osteoporosis	3.83e-05	0.000238	CcSEcCtD
Nilotinib—Diarrhoea—Estradiol—osteoporosis	3.71e-05	0.000231	CcSEcCtD
Nilotinib—Dizziness—Estradiol—osteoporosis	3.58e-05	0.000223	CcSEcCtD
Nilotinib—Vomiting—Estradiol—osteoporosis	3.44e-05	0.000214	CcSEcCtD
Nilotinib—Rash—Estradiol—osteoporosis	3.41e-05	0.000213	CcSEcCtD
Nilotinib—Dermatitis—Estradiol—osteoporosis	3.41e-05	0.000212	CcSEcCtD
Nilotinib—Headache—Estradiol—osteoporosis	3.39e-05	0.000211	CcSEcCtD
Nilotinib—Nausea—Estradiol—osteoporosis	3.22e-05	0.0002	CcSEcCtD
Nilotinib—MAPK14—Developmental Biology—TNF—osteoporosis	3.5e-06	2.53e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—osteoporosis	3.49e-06	2.53e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP27A1—osteoporosis	3.49e-06	2.53e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—LEP—osteoporosis	3.49e-06	2.53e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IGF1—osteoporosis	3.47e-06	2.51e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1B—osteoporosis	3.47e-06	2.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IRS1—osteoporosis	3.47e-06	2.51e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ADCY5—osteoporosis	3.47e-06	2.51e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.46e-06	2.51e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—MYC—osteoporosis	3.46e-06	2.5e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—RAP1A—osteoporosis	3.46e-06	2.5e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GPX1—osteoporosis	3.45e-06	2.5e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—TGFB1—osteoporosis	3.45e-06	2.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IRS1—osteoporosis	3.45e-06	2.5e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ATIC—osteoporosis	3.44e-06	2.49e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PNP—osteoporosis	3.44e-06	2.49e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6R—osteoporosis	3.44e-06	2.49e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IRS2—osteoporosis	3.43e-06	2.49e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6R—osteoporosis	3.42e-06	2.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SPP1—osteoporosis	3.4e-06	2.46e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ACP5—osteoporosis	3.4e-06	2.46e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.39e-06	2.46e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.39e-06	2.45e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ACP5—osteoporosis	3.37e-06	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ESR1—osteoporosis	3.36e-06	2.43e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TPI1—osteoporosis	3.35e-06	2.43e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MTHFR—osteoporosis	3.33e-06	2.41e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ESR1—osteoporosis	3.33e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.32e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ENO1—osteoporosis	3.3e-06	2.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6R—osteoporosis	3.26e-06	2.36e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PSMA2—osteoporosis	3.25e-06	2.35e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PSMA5—osteoporosis	3.25e-06	2.35e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IRS2—osteoporosis	3.24e-06	2.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6R—osteoporosis	3.24e-06	2.35e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KL—osteoporosis	3.24e-06	2.35e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MTHFR—osteoporosis	3.19e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TGFB1—osteoporosis	3.18e-06	2.3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LEP—osteoporosis	3.18e-06	2.3e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IRS2—osteoporosis	3.17e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ADCY5—osteoporosis	3.16e-06	2.29e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TPI1—osteoporosis	3.16e-06	2.29e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—P4HB—osteoporosis	3.15e-06	2.28e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—osteoporosis	3.15e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IRS1—osteoporosis	3.14e-06	2.27e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—osteoporosis	3.13e-06	2.27e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TPI1—osteoporosis	3.13e-06	2.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IRS1—osteoporosis	3.11e-06	2.25e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ADCY5—osteoporosis	3.1e-06	2.24e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GAPDH—osteoporosis	3.09e-06	2.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IRS2—osteoporosis	3.07e-06	2.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SPP1—osteoporosis	3.06e-06	2.22e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ESR1—osteoporosis	3.03e-06	2.2e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—POMC—osteoporosis	3.02e-06	2.19e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.01e-06	2.18e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—RAP1A—osteoporosis	3.01e-06	2.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LEP—osteoporosis	3.01e-06	2.18e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IRS1—osteoporosis	3e-06	2.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—POMC—osteoporosis	3e-06	2.17e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SPP1—osteoporosis	3e-06	2.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—osteoporosis	2.98e-06	2.16e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—osteoporosis	2.98e-06	2.15e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—P4HB—osteoporosis	2.97e-06	2.15e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—osteoporosis	2.96e-06	2.15e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—osteoporosis	2.96e-06	2.14e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6R—osteoporosis	2.95e-06	2.14e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—P4HB—osteoporosis	2.94e-06	2.13e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ADCY5—osteoporosis	2.94e-06	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADCY5—osteoporosis	2.94e-06	2.13e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GPX1—osteoporosis	2.93e-06	2.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—OXCT1—osteoporosis	2.93e-06	2.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CA2—osteoporosis	2.93e-06	2.12e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6R—osteoporosis	2.92e-06	2.12e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GAPDH—osteoporosis	2.91e-06	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1—osteoporosis	2.91e-06	2.11e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GAPDH—osteoporosis	2.89e-06	2.09e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1—osteoporosis	2.88e-06	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	2.87e-06	2.08e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MGLL—osteoporosis	2.85e-06	2.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SPP1—osteoporosis	2.84e-06	2.06e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—RAP1A—osteoporosis	2.84e-06	2.05e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IRS1—osteoporosis	2.83e-06	2.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—osteoporosis	2.82e-06	2.04e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6R—osteoporosis	2.82e-06	2.04e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—osteoporosis	2.82e-06	2.04e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—RAP1A—osteoporosis	2.81e-06	2.04e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ENO1—osteoporosis	2.79e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IRS1—osteoporosis	2.77e-06	2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	2.77e-06	2e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PSMA2—osteoporosis	2.75e-06	1.99e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PSMA5—osteoporosis	2.75e-06	1.99e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—POMC—osteoporosis	2.73e-06	1.98e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IRS2—osteoporosis	2.71e-06	1.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LEP—osteoporosis	2.71e-06	1.96e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTHFR—osteoporosis	2.7e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—osteoporosis	2.69e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—osteoporosis	2.68e-06	1.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	2.68e-06	1.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—osteoporosis	2.67e-06	1.93e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6R—osteoporosis	2.66e-06	1.93e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LEP—osteoporosis	2.65e-06	1.92e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP19A1—osteoporosis	2.64e-06	1.91e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—osteoporosis	2.63e-06	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1—osteoporosis	2.62e-06	1.9e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—osteoporosis	2.62e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—osteoporosis	2.61e-06	1.89e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—osteoporosis	2.6e-06	1.88e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6R—osteoporosis	2.6e-06	1.88e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—osteoporosis	2.6e-06	1.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	2.59e-06	1.87e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—POMC—osteoporosis	2.58e-06	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IRS2—osteoporosis	2.57e-06	1.86e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—osteoporosis	2.55e-06	1.85e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—osteoporosis	2.55e-06	1.85e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—POMC—osteoporosis	2.55e-06	1.85e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—osteoporosis	2.54e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADCY5—osteoporosis	2.54e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ESR1—osteoporosis	2.53e-06	1.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	2.52e-06	1.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LEP—osteoporosis	2.51e-06	1.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—osteoporosis	2.49e-06	1.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	2.48e-06	1.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—osteoporosis	2.48e-06	1.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—osteoporosis	2.47e-06	1.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—osteoporosis	2.47e-06	1.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPP1—osteoporosis	2.46e-06	1.78e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.45e-06	1.78e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO1—osteoporosis	2.43e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—IDH2—osteoporosis	2.43e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	2.42e-06	1.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ESR1—osteoporosis	2.4e-06	1.74e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PSMA5—osteoporosis	2.4e-06	1.74e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PSMA2—osteoporosis	2.4e-06	1.74e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IRS1—osteoporosis	2.36e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—osteoporosis	2.33e-06	1.68e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO1—osteoporosis	2.29e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.28e-06	1.65e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—osteoporosis	2.28e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO1—osteoporosis	2.27e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	2.27e-06	1.64e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PSMA2—osteoporosis	2.26e-06	1.64e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PSMA5—osteoporosis	2.26e-06	1.64e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—osteoporosis	2.25e-06	1.63e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—osteoporosis	2.25e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IRS1—osteoporosis	2.24e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PSMA2—osteoporosis	2.24e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PSMA5—osteoporosis	2.24e-06	1.62e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	2.24e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP19A1—osteoporosis	2.23e-06	1.62e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6R—osteoporosis	2.22e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IRS2—osteoporosis	2.22e-06	1.61e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ACP5—osteoporosis	2.22e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—osteoporosis	2.19e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—osteoporosis	2.19e-06	1.59e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—osteoporosis	2.19e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—osteoporosis	2.17e-06	1.57e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—osteoporosis	2.16e-06	1.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—osteoporosis	2.16e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ADCY5—osteoporosis	2.16e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—osteoporosis	2.15e-06	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GPX1—osteoporosis	2.15e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—osteoporosis	2.14e-06	1.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—osteoporosis	2.13e-06	1.54e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—osteoporosis	2.13e-06	1.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6R—osteoporosis	2.11e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—osteoporosis	2.09e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	2.08e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—osteoporosis	2.08e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ESR1—osteoporosis	2.07e-06	1.5e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TPI1—osteoporosis	2.06e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—osteoporosis	2.03e-06	1.47e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—osteoporosis	1.98e-06	1.44e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP19A1—osteoporosis	1.95e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—P4HB—osteoporosis	1.94e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IRS1—osteoporosis	1.94e-06	1.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—osteoporosis	1.92e-06	1.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—osteoporosis	1.92e-06	1.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—osteoporosis	1.92e-06	1.39e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GAPDH—osteoporosis	1.9e-06	1.38e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—osteoporosis	1.87e-06	1.35e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—osteoporosis	1.86e-06	1.35e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RAP1A—osteoporosis	1.85e-06	1.34e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.83e-06	1.33e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—osteoporosis	1.83e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADCY5—osteoporosis	1.82e-06	1.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6R—osteoporosis	1.82e-06	1.32e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—osteoporosis	1.82e-06	1.32e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.82e-06	1.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—osteoporosis	1.8e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—osteoporosis	1.75e-06	1.27e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—osteoporosis	1.74e-06	1.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—osteoporosis	1.74e-06	1.26e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—osteoporosis	1.73e-06	1.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—osteoporosis	1.73e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—osteoporosis	1.69e-06	1.23e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—osteoporosis	1.68e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—osteoporosis	1.65e-06	1.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—osteoporosis	1.6e-06	1.16e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADCY5—osteoporosis	1.59e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—osteoporosis	1.59e-06	1.15e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—osteoporosis	1.58e-06	1.15e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—osteoporosis	1.58e-06	1.14e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—osteoporosis	1.57e-06	1.14e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—osteoporosis	1.57e-06	1.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—osteoporosis	1.56e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—osteoporosis	1.54e-06	1.12e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—osteoporosis	1.54e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—osteoporosis	1.53e-06	1.11e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—osteoporosis	1.52e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO1—osteoporosis	1.5e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADCY5—osteoporosis	1.5e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—osteoporosis	1.49e-06	1.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—osteoporosis	1.49e-06	1.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	1.49e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADCY5—osteoporosis	1.49e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—osteoporosis	1.48e-06	1.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSMA2—osteoporosis	1.48e-06	1.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSMA5—osteoporosis	1.48e-06	1.07e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—osteoporosis	1.46e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—osteoporosis	1.45e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—osteoporosis	1.44e-06	1.05e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—osteoporosis	1.38e-06	9.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—osteoporosis	1.37e-06	9.89e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—osteoporosis	1.34e-06	9.74e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—osteoporosis	1.34e-06	9.72e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	1.34e-06	9.71e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—osteoporosis	1.32e-06	9.53e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—osteoporosis	1.31e-06	9.52e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—osteoporosis	1.31e-06	9.51e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—osteoporosis	1.3e-06	9.43e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—osteoporosis	1.25e-06	9.09e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—osteoporosis	1.25e-06	9.04e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—osteoporosis	1.24e-06	9.02e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.2e-06	8.68e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—osteoporosis	1.19e-06	8.58e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—osteoporosis	1.17e-06	8.47e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—osteoporosis	1.16e-06	8.39e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—osteoporosis	1.12e-06	8.12e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—osteoporosis	1.1e-06	7.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—osteoporosis	1.09e-06	7.91e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—osteoporosis	1.08e-06	7.81e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—osteoporosis	1.08e-06	7.8e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—osteoporosis	1.01e-06	7.32e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—osteoporosis	9.9e-07	7.17e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADCY5—osteoporosis	9.79e-07	7.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—osteoporosis	9.76e-07	7.07e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—osteoporosis	9.38e-07	6.79e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—osteoporosis	9.01e-07	6.52e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—osteoporosis	8.11e-07	5.87e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—osteoporosis	7.2e-07	5.22e-06	CbGpPWpGaD
